GLUT1 Deficiency Syndrome—Early Treatment Maintains Cognitive Development? (Literature Review and Case Report)
Authors:
- Ivana KolicIKIvana Kolic
- Jelena Radic NisevicJNJelena Radic Nisevic
- Inge Vlasic CicvaricICInge Vlasic Cicvaric
- Ivona Butorac AhelIAIvona Butorac Ahel
- Kristina Lah TomulicKTKristina Lah Tomulic
- Silvije SeguljaSSSilvije Segulja
- Kristina Baraba DekanicKDKristina Baraba Dekanic
- Senada SerifiSSSenada Serifi
- Aleksandar OvukaAOAleksandar Ovuka
- Igor PrpicIPIgor Prpic
Open Access
Abstract
Glucose transporter type 1 (GLUT1) is the most important energy carrier of the brain across the blood–brain barrier, and a genetic defect of GLUT1 is known as GLUT1 deficiency syndrome (GLUT1DS). It is characterized by early infantile seizures, developmental delay, microcephaly, ataxia, and various paroxysmal neurological phenomena. In most cases, GLUT1DS is caused by heterozygous single-nucleotide variants (SNVs) in the SLC2A1 gene that provoke complete or severe impairment of the functionality and/or expression of GLUT1 in the brain. Despite the rarity of these diseases, GLUT1DS is of high clinical interest since a very effective therapy, the ketogenic diet, can improve or reverse symptoms, especially if it is started as early as possible. We present a clinical phenotype, biochemical analysis, electroencephalographic and neuropsychological features of an 11-month-old boy with myoclonic seizures, hypogammaglobulinemia, and mildly impaired gross motor development. Using sequence analysis and deletion/duplication testing, deletion of an entire coding sequence in the SLC2A1 gene was detected. Early introduction of a modified Atkins diet maintained a seizure-free period without antiseizure medications and normal cognitive development in the follow-up period. Our report summarizes the clinical features of GLUT1 syndromes and discusses the importance of early identification and molecular confirmation of GLUT1DS as a treatable metabolic disorder.Keywords
This publication has 31 references indexed in Scilit:
- Toll-like receptor 4 signaling in T cells promotes autoimmune inflammationProceedings of the National Academy of Sciences, 2012
- Saturated Fatty Acid and TLR Signaling Link β Cell Dysfunction and Islet InflammationCell Metabolism, 2012
- Glut1 deficiency: When to suspect and how to diagnose?European Journal of Paediatric Neurology, 2012
- A modified Atkins diet is promising as a treatment for glucose transporter type 1 deficiency syndromeDevelopmental Medicine & Child Neurology, 2011
- Uncovering microdeletions in patients with severe Glut-1 deficiency syndrome using SNP oligonucleotide microarray analysisMolecular Genetics and Metabolism, 2010
- Glucose transporter type 1 deficiency: Ketogenic diet in three patients with atypical phenotypeBrain and Development, 2010
- Glucose transporter-1 deficiency syndrome: the expanding clinical and genetic spectrum of a treatable disorderBrain, 2010
- Glucose transporter deficiency syndrome (GLUT1DS) and the ketogenic dietEpilepsia, 2008
- GLUT1 deficiency syndrome – 2007 updateDevelopmental Medicine & Child Neurology, 2007
- Defective Glucose Transport across the Blood-Brain Barrier as a Cause of Persistent Hypoglycorrhachia, Seizures, and Developmental DelayNew England Journal of Medicine, 1991